Ketoconazole Side Effects
Not all side effects for ketoconazole may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.
For the Consumer
Applies to ketoconazole: oral tablet
In addition to its needed effects, some unwanted effects may be caused by ketoconazole. In the event that any of these side effects do occur, they may require medical attention.
You should check with your doctor immediately if any of these side effects occur when taking ketoconazole:Rare
- Back, leg, or stomach pains
- black, tarry stools
- bleeding gums
- blood in the urine or stools
- blurred vision
- burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
- change in color vision
- change in the ability to see colors, especially blue or yellow
- chest pain
- dark urine
- difficulty seeing at night
- difficulty swallowing
- fast heartbeat
- general body swelling
- increased sensitivity of the eyes to sunlight
- joint pain, stiffness, or swelling
- light-colored stools
- loss of appetite
- mood or mental changes
- nausea or vomiting, severe
- painful or difficult urination
- pale skin
- pinpoint red spots on the skin
- puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
- redness of the skin
- skin rash, hives, itching
- sore throat
- sores, ulcers, or white spots on the lips or in the mouth
- swelling of the eyelids, face, lips, hands, or feet
- swollen glands
- tightness in the chest
- trouble sleeping
- troubled breathing or swallowing
- unusual bleeding or bruising
- unusual tiredness or weakness
- vision changes
- yellow eyes or skin
Some of the side effects that can occur with ketoconazole may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:Rare
- Change in number of sperm and their ability to move
- decreased interest in sexual intercourse
- hair loss or thinning of the hair
- inability to have or keep an erection
- loss in sexual ability, desire, drive, or performance
- sleepiness or unusual drowsiness
- swelling of the breasts or breast soreness for both female and male
For Healthcare Professionals
Applies to ketoconazole: compounding powder, oral tablet
Ketoconazole therapy has commonly been associated with transient elevations in liver enzymes, which have resolved despite continued therapy.
Serious hepatotoxicity has been reported with both high doses for short durations and low doses for long therapy durations. Hepatic injury has usually (but not always) been reversible with discontinuation of ketoconazole therapy. Hepatitis has been reported in children.
Hepatotoxicity has been reported with oral ketoconazole rechallenge.
Severe hepatotoxicity (hepatocellular, cholestatic, or mixed) generally occurred after 1 or 2 months of therapy. Hepatic function usually returned to normal within 1 month, but cases of hepatic failure and death have occurred.
Frequency not reported: Hepatitis, jaundice, abnormal hepatic function, hepatotoxicity, transient elevations of liver enzymes, severe hepatotoxicity (hepatocellular, cholestatic, or mixed)
Postmarketing reports: Serious hepatotoxicity including cholestatic hepatitis, biopsy-confirmed hepatic necrosis, cirrhosis, hepatic failure (including cases resulting in death or requiring liver transplantation)
Frequency not reported: Orthostatic hypotension, QT interval prolongation (sometimes resulting in life-threatening ventricular dysrhythmias such as torsades de pointes)
Ketoconazole inhibits hydroxylation of deoxycortisol, which results in diminished cortisol production, especially when given in divided doses. In some patients, symptomatic adrenal insufficiency may occur, presenting with hyponatremia, hyperkalemia, hypotension, lethargy, depression, and malaise.
A 77-year-old male with prostate cancer experienced adrenal crisis coincident with ketoconazole therapy. He presented with progressive right lower extremity weakness, debilitating low back pain, and a serum prostate-specific antigen level of 78.8 ng/mL. He was given ketoconazole 200 mg orally four times daily to reduce serum testosterone levels. Nine days after initiating ketoconazole therapy, he experienced generalized weakness, abdominal pain, nausea with vomiting, and severely diminished mentation. The urology service was advised of the patient's admission and suggested that adrenal insufficiency related to high-dose ketoconazole therapy should be considered in the differential diagnosis. However, a serum cortisol level was not obtained prior to steroid treatment. An ACTH stimulation test performed 2 days later showed no evidence of underlying adrenal insufficiency when the patient was no longer being given ketoconazole.
Rare (less than 0.1%): Hypothyroidism
Frequency not reported: Inhibition of cortisol production (sometimes resulting in symptomatic adrenal insufficiency), adrenal crisis
Postmarketing reports: Adrenocortical insufficiency
Frequency not reported: Erythema multiforme, rash, dermatitis, erythema, urticaria, pruritus, alopecia, xeroderma, dry skin, bruising, loss of scalp hair, worsening loss of scalp hair, desquamation
Postmarketing reports: Acute generalized exanthematous pustulosis, photosensitivity
Common (1% to 10%): Gastrointestinal complaints (including nausea, vomiting)
Frequency not reported: Diarrhea, constipation, abdominal pain, upper abdominal pain, dry mouth, dysgeusia, dyspepsia, flatulence, tongue discoloration, stomatitis
Gastrointestinal intolerance may resolve with continued therapy and may improve if ketoconazole is taken with food.
A 23-year-old female with vaginal discharge experienced fatal aplastic anemia coincident with ketoconazole therapy. She was admitted with widespread purpuric lesions on her face, arms, and legs. She had taken ketoconazole 200 mg twice daily for vaginal discharge for 4 days before admission. Ketoconazole was discontinued on admission. The patient was diagnosed with aplastic anemia based on clinical findings. The patient did not respond to therapy and died of disseminated candidiasis 2 months later.
Rare (less than 0.1%): Hemolytic anemia
Frequency not reported: Platelet count decreased, fatal aplastic anemia
Postmarketing reports: Thrombocytopenia
Frequency not reported: Anaphylactoid reaction, hypersensitivity reactions (including urticaria), anaphylaxis (sometimes after first dose), cross-sensitivity between imidazoles, drug hypersensitivity (presenting as rash, erythema, pruritus)
Postmarketing reports: Allergic conditions including anaphylactic shock, anaphylactic reaction, angioneurotic edema
A 72-year-old female with a Candida albicans infection experienced a severe reaction of refractory anaphylactic shock coincident with ketoconazole therapy. She was initially given oral ketoconazole 200 mg twice daily. She developed hypotension over the first 2 days of treatment (BP 136/82 mmHg at baseline; 90/50 mmHg on day 2). Severe hypotension (BP 90/49 mmHg) unresponsive to fluid therapy or high-dose dopamine developed on day 4 of treatment. When laboratory tests revealed a high level of plasma tryptase, anaphylactic redistribution shock was diagnosed. Her vital signs became more stable after therapy with hydrocortisone and epinephrine infusion.
Frequency not reported: Menstrual disorder, serum testosterone decreased, gynecomastia (in males), breast tenderness (in males), oligospermia, polymenorrhea anovulatory cycles, anovulatory oligomenorrhea
Postmarketing reports: Erectile dysfunction, azoospermia (with doses higher than recommended dose of 200 to 400 mg per day)
Gynecomastia and breast tenderness have been reported in male patients. Gynecomastia in males resulted from decreased steroidogenesis and testosterone production, which led to an increased estrogen to testosterone ratio.
Rare (less than 0.1%): Hypoglycemia
Frequency not reported: Alcohol intolerance, anorexia, hyperlipidemia, increased appetite, transient fall in serum cholesterol with an increase in triglycerides
Frequency not reported: Headache, somnolence, dizziness, paresthesia
Postmarketing reports: Reversible increased intracranial pressure (e.g., papilledema, fontanel bulging in infants)
Frequency not reported: Fatigue, asthenia, hot flush, malaise, peripheral edema, pyrexia, chills
Frequency not reported: Myalgia
Postmarketing reports: Arthralgia
Rare (less than 0.1%): Confusion, suicidal tendencies
Frequency not reported: Insomnia, nervousness, paranoid delusions
Paranoid delusions have been reported in a patient treated with ketoconazole for cutaneous leishmaniasis.
Frequency not reported: Photophobia
Frequency not reported: Epistaxis
More about ketoconazole
- Other brands: Nizoral
Related treatment guides
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.